Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.

Buelli S, Zoja C, Remuzzi G, Morigi M.

Microorganisms. 2019 Jan 10;7(1). pii: E15. doi: 10.3390/microorganisms7010015. Review.

2.

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, Villa S, Morigi M, Remuzzi G, Benigni A, Zoja C.

JCI Insight. 2018 Aug 9;3(15). pii: 98720. doi: 10.1172/jci.insight.98720. eCollection 2018 Aug 9.

3.

Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Zoja C, Buelli S, Morigi M.

Pediatr Nephrol. 2019 Mar;34(3):379-388. doi: 10.1007/s00467-017-3850-x. Epub 2017 Dec 6. Review.

PMID:
29214442
4.

Untangling the Knot in Diabetic Nephropathy: The Unanticipated Role of Glycocalyx in the Antiproteinuric Effect of Endothelin Receptor Antagonists.

Buelli S, Perico L, Benigni A.

Diabetes. 2016 Aug;65(8):2115-7. doi: 10.2337/dbi16-0020. No abstract available.

5.

A previously unrecognized role of C3a in proteinuric progressive nephropathy.

Morigi M, Locatelli M, Rota C, Buelli S, Corna D, Rizzo P, Abbate M, Conti D, Perico L, Longaretti L, Benigni A, Zoja C, Remuzzi G.

Sci Rep. 2016 Jun 27;6:28445. doi: 10.1038/srep28445.

6.

Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease.

Buelli S, Perico L, Galbusera M, Abbate M, Morigi M, Novelli R, Gagliardini E, Tentori C, Rottoli D, Sabadini E, Saito T, Kawano M, Saeki T, Zoja C, Remuzzi G, Benigni A.

EBioMedicine. 2015 Mar 6;2(5):456-66. doi: 10.1016/j.ebiom.2015.03.003. eCollection 2015 May.

7.

Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II.

Macconi D, Perico L, Longaretti L, Morigi M, Cassis P, Buelli S, Perico N, Remuzzi G, Benigni A.

PLoS One. 2015 May 19;10(5):e0127172. doi: 10.1371/journal.pone.0127172. eCollection 2015.

8.

Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.

Zoja C, Corna D, Locatelli M, Rottoli D, Pezzotta A, Morigi M, Zanchi C, Buelli S, Guglielmotti A, Perico N, Remuzzi A, Remuzzi G.

Nephron. 2015;129(1):52-61. doi: 10.1159/000369149. Epub 2014 Dec 17.

9.

Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.

Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M.

J Am Soc Nephrol. 2014 Aug;25(8):1786-98. doi: 10.1681/ASN.2013050450. Epub 2014 Feb 27.

10.

β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.

Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A.

J Am Soc Nephrol. 2014 Mar;25(3):523-33. doi: 10.1681/ASN.2013040362. Epub 2013 Dec 26.

11.

Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway.

Gagliardini E, Perico N, Rizzo P, Buelli S, Longaretti L, Perico L, Tomasoni S, Zoja C, Macconi D, Morigi M, Remuzzi G, Benigni A.

Am J Pathol. 2013 Jul;183(1):119-30. doi: 10.1016/j.ajpath.2013.03.025. Epub 2013 May 23.

12.

Endothelin in chronic proteinuric kidney disease.

Gagliardini E, Buelli S, Benigni A.

Contrib Nephrol. 2011;172:171-184. doi: 10.1159/000328697. Epub 2011 Aug 30. Review.

PMID:
21893998
13.

MYO1E mutations and childhood familial focal segmental glomerulosclerosis.

Mele C, Iatropoulos P, Donadelli R, Calabria A, Maranta R, Cassis P, Buelli S, Tomasoni S, Piras R, Krendel M, Bettoni S, Morigi M, Delledonne M, Pecoraro C, Abbate I, Capobianchi MR, Hildebrandt F, Otto E, Schaefer F, Macciardi F, Ozaltin F, Emre S, Ibsirlioglu T, Benigni A, Remuzzi G, Noris M; PodoNet Consortium.

N Engl J Med. 2011 Jul 28;365(4):295-306. doi: 10.1056/NEJMoa1101273. Epub 2011 Jul 14.

14.

Membranous nephropathy associated with IgG4-related disease.

Cravedi P, Abbate M, Gagliardini E, Galbusera M, Buelli S, Sabadini E, Marasà M, Beck LH Jr, Salant DJ, Benigni A, D'Agati V, Remuzzi G.

Am J Kidney Dis. 2011 Aug;58(2):272-5. doi: 10.1053/j.ajkd.2011.05.002. Epub 2011 Jun 12.

PMID:
21658826
15.

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.

Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C.

J Immunol. 2011 Jul 1;187(1):172-80. doi: 10.4049/jimmunol.1100491. Epub 2011 Jun 3.

16.

Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.

Zoja C, Buelli S, Morigi M.

Pediatr Nephrol. 2010 Nov;25(11):2231-40. doi: 10.1007/s00467-010-1522-1. Epub 2010 Apr 28. Review.

PMID:
20424866
17.

Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells.

Buelli S, Abbate M, Morigi M, Moioli D, Zanchi C, Noris M, Zoja C, Pusey CD, Zipfel PF, Remuzzi G.

Kidney Int. 2009 May;75(10):1050-9. doi: 10.1038/ki.2009.8. Epub 2009 Feb 25.

18.

Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides.

Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E, Noris M, Buelli S, Zoja C, Corna D, Mele C, Fanelli R, Remuzzi G, Benigni A.

J Am Soc Nephrol. 2009 Jan;20(1):123-30. doi: 10.1681/ASN.2007111233. Epub 2008 Dec 17.

19.

Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.

Zanchi C, Zoja C, Morigi M, Valsecchi F, Liu XY, Rottoli D, Locatelli M, Buelli S, Pezzotta A, Mapelli P, Geelen J, Remuzzi G, Hawiger J.

J Immunol. 2008 Jul 15;181(2):1460-9.

20.

Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling.

Morigi M, Buelli S, Zanchi C, Longaretti L, Macconi D, Benigni A, Moioli D, Remuzzi G, Zoja C.

Am J Pathol. 2006 Dec;169(6):1965-75.

21.

Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention.

Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, Bonomelli M, Mundel P, Endlich K, Remuzzi A, Remuzzi G.

Am J Pathol. 2006 Apr;168(4):1073-85.

22.

In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies.

Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C, Galbusera M, Gastoldi S, Mundel P, Remuzzi G, Benigni A.

Am J Pathol. 2005 May;166(5):1309-20.

23.

Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation.

Galbusera M, Buelli S, Gastoldi S, Macconi D, Angioletti S, Testa C, Remuzzi G, Morigi M.

Xenotransplantation. 2005 Mar;12(2):110-20.

PMID:
15693841
24.

Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways.

Donadelli R, Zanchi C, Morigi M, Buelli S, Batani C, Tomasoni S, Corna D, Rottoli D, Benigni A, Abbate M, Remuzzi G, Zoja C.

J Am Soc Nephrol. 2003 Oct;14(10):2436-46.

25.

Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway.

Morigi M, Macconi D, Zoja C, Donadelli R, Buelli S, Zanchi C, Ghilardi M, Remuzzi G.

J Am Soc Nephrol. 2002 May;13(5):1179-89.

Supplemental Content

Loading ...
Support Center